Pan-cancer Expression Analysis of CXCL1/8/10 and Their Relationship with Prognosis and Tumor Microenvironment
DOI:
https://doi.org/10.54097/mtf9ks16Keywords:
CXCL1/8/10, Pan-cancer, Tumor Microenvironment, Stemness Index, BioinformaticsAbstract
Objective To analyze the expression characteristics and prognostic value of CXCL family members (CXCL1/8/10) across pan-cancer using bioinformatics approaches. Methods Transcriptomic and clinical data of 33 tumor types were obtained from the TCGA database. Differential expression was evaluated by the Wilcoxon rank-sum test. Prognostic significance was assessed using Kaplan-Meier survival curves and univariate Cox regression. Spearman correlation analysis was applied to examine associations with immune subtypes, tumor stemness scores, tumor microenvironment (TME) components, tumor mutational burden (TMB), and microsatellite instability (MSI). Results CXCL1/8/10 exhibited marked expression heterogeneity across cancer types, with CXCL10 showing relatively high expression in the majority of tumors. The expression levels of all three genes were significantly associated with overall survival and showed varying degrees of correlation with immune infiltration subtypes, stromal/immune scores, and tumor stemness scores. After adjusting for tumor purity, the correlations between CXCL10 and TMB/MSI remained significant in several cancer types. Conclusion CXCL1/8/10 display significant expression heterogeneity in pan-cancer and are closely associated with the immune microenvironment and tumor stemness, representing potential prognostic biomarkers and therapeutic targets for specific cancer types.
Downloads
References
[1] Zhou, C., Gao, Y., Ding, P., & et al. (2023). The role of CXCL family members in different diseases. Cell Death Discovery, 9(1), 212. https://doi.org/10.1038/s41420 023 01476 5.
[2] Hughes, C. E., & Nibbs, R. J. B. (2018). A guide to chemokines and their receptors. The FEBS Journal, 285(16), 2944 2971. https://doi.org/10.1111/febs.14466.
[3] Cabrero de las Heras, S., & et al. (2018). CXC chemokines as biomarkers in colorectal cancer. World Journal of Gastroenterology, 24(42), 4738 4749. https://doi.org/10. 3748/wjg. v24. i42.4738.
[4] Zdanowska, N., & et al. (2021). The role of chemokines in psoriasis an overview. Medicina (Kaunas), 57(8). https://doi. org/ 10. 3390/medicina57080820.
[5] Sun, Y., & et al. (2021). Genome wide identification of the JAZ gene family in tomato. International Journal of Molecular Sciences, 22(18). https://doi.org/10.3390/ijms22189744.
[6] Han, Y., & Luthe, D. (2021). Identification and evolution analysis of the JAZ gene family in maize. BMC Genomics, 22(1), 256. https://doi.org/10.1186/s12864 021 07572 4.
[7] Waterhouse, A., & et al. (2018). SWISS MODEL: homology modelling of protein structures and complexes. Nucleic Acids Research, 46(W1), W296 W303. https://doi.org/ 10.1093/ nar/ gky427.
[8] Chen, C., & et al. (2020). TBtools: an integrative toolkit developed for interactive analyses of big biological data. Molecular Plant, 13(8), 1194 1202. https://doi.org/10.1016/ j.molp. 2020.06.009.
[9] Goldman, M. J., & et al. (2020). Visualizing and interpreting cancer genomics data via the Xena platform. Nature Biotechnology, 38(6), 675 678. https://doi.org/10. 1038/ s41 587 020 0546 8.
[10] Malta, T. M., & et al. (2018). Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell, 173(2), 338 354. https://doi.org/10. 1016/j.cell. 2018. 03. 034.
[11] Wu, X., & et al. (2020). CXCL10 mediates breast cancer tamoxifen resistance and promotes estrogen dependent and independent proliferation. Molecular and Cellular Endocrinology, 512, 110866. https://doi. org/10. 1016/j. mce. 2020. 110866.
[12] Zhou, X., & et al. (2021). CXC chemokines as therapeutic targets and prognostic biomarkers in skin cutaneous melanoma microenvironment. Frontiers in Oncology, 11, 619003. https:// doi. org/10.3389/fonc.2021.619003.
[13] Gorbachev, A. V., & et al. (2007). CXC chemokine ligand 9/monokine induced by IFN gamma production by tumor cells is critical for T cell mediated suppression of cutaneous tumors. Journal of Immunology, 178(4), 2278 2286. https://doi.org/10. 4049/ jimmunol.178.4.2278.
[14] Lee, H. J., & et al. (2014). CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting. World Journal of Gastroenterology, 20(7), 1681 1693. https://doi.org/10.3748/wjg.v20.i7.1681.
[15] Miyazaki, H., & et al. (2013). Chemokines, chemokine receptors and the gastrointestinal system. World Journal of Gastroenterology, 19(19), 2847 2863. https://doi.org/10. 3748/wjg. v19.i19.2847.
[16] Kitadai, Y., & et al. (1998). Expression of interleukin 8 correlates with vascularity in human gastric carcinomas. The American Journal of Pathology, 152(1), 93 100.
[17] Torti, D., & et al. (2012). A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. International Journal of Cancer, 130(6), 1357 1366. https://doi.org/10. 1002/ijc. 26162.
[18] Rhee, J. K., & et al. (2018). Impact of tumor purity on immune gene expression and clustering analyses across multiple cancer types. Cancer Immunology Research, 6(1), 87 97. https://doi. org/ 10.1158/2326 6066.CIR 17 0207.
[19] Aran, D., & et al. (2015). Systematic pan cancer analysis of tumour purity. Nature Communications, 6, 8971. https://doi. org/ 10.1038/ncomms9971.
[20] Li, B., & et al. (2016). Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biology, 17(1), 174. https://doi.org/10. 1186/ s130 59 0 16 1060 7.
[21] Rooney, M. S., & et al. (2015). Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell, 160(1 2), 48 61. https://doi.org/ 10.1016/j. cell. 2014.12.033.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
